|View printer-friendly version|
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
- Cowen and Company’s 38th Annual
Health Care Conferenceon Tuesday, March 13, 2018, at 8:40 a.m. Eastern Timein Boston.
- Oppenheimer’s 28th Annual Healthcare Conference on
Tuesday, March 20, 2018, at 10:55 a.m. Eastern Timein New York.
Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.